

Vittorina Zagonel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2791832/publications.pdf>

Version: 2024-02-01

209
papers

9,563
citations

50170

46
h-index

46693

89
g-index

210
all docs

210
docs citations

210
times ranked

11886
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	13.9	845
2	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
3	Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 494-502.	0.8	765
4	Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 26-32.	3.0	261
5	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 110-119.	5.1	238
6	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
7	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. <i>Blood</i> , 1997, 90, 776-782.	0.6	217
8	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
9	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015, 17, 708-717.	0.6	191
10	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , 1996, 94, 533-543.	1.2	187
11	Validation of a multidimensional evaluation scale for use in elderly cancer patients. , 1996, 77, 395-401.		181
12	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002, 99, 856-862.	0.6	155
13	Gender medicine: a task for the third millennium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 713-727.	1.4	155
14	Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 65, 61-68.	1.3	130
15	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129
16	Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. <i>European Journal of Cancer</i> , 2016, 69, 110-118.	1.3	121
17	Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. , 1998, 58, 105-109.		112
18	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997, 89, 2048-2059.	0.6	110

#	ARTICLE	IF	CITATIONS
19	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , 2021, 13, 47.	1.7	106
20	Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). <i>Journal of Cancer</i> , 2016, 7, 131-135.	1.2	98
21	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma â€” The SHELTER study. <i>Journal of Hepatology</i> , 2016, 65, 280-288.	1.8	98
22	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
23	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
24	Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. <i>Blood</i> , 2002, 100, 1972-1976.	0.6	91
25	Burkitt's lymphoma in adults with and without human immunodeficiency virus infection. <i>Cancer</i> , 1998, 82, 766-774.	2.0	87
26	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87
27	Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients. <i>Clinical Journal of Pain</i> , 2011, 27, 9-18.	0.8	86
28	5-Aza-2â€²-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003, 101, 4644-4646.	0.6	78
29	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	0.9	73
30	Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 94-102.	2.0	73
31	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 229-236.	2.0	72
32	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	0.6	71
33	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
34	Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey. <i>Nutrition</i> , 2016, 32, 1028-1032.	1.1	69
35	Head and neck cancer and ageing: a retrospective study in 438 patients. <i>Journal of Laryngology and Otology</i> , 1990, 104, 634-640.	0.4	65
36	Prevalence of functional disability among elderly patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 269-273.	2.0	65

#	ARTICLE	IF	CITATIONS
37	Early HER2 dysregulation in gastric and oesophageal carcinogenesis. <i>Histopathology</i> , 2012, 61, 769-776.	1.6	64
38	Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 295-301.	1.0	60
39	Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards. <i>BMJ Supportive and Palliative Care</i> , 2011, 1, 281-287.	0.8	56
40	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
41	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	55
42	Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma. <i>Oncologist</i> , 2015, 20, 562-567.	1.9	55
43	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1069-1077.	1.2	52
44	Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 514-519.	0.6	50
45	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. <i>Journal of Neuro-Oncology</i> , 2015, 122, 189-196.	1.4	50
46	The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. <i>Human Pathology</i> , 2013, 44, 1804-1810.	1.1	49
47	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 549-557.	0.7	49
48	The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. <i>Translational Oncology</i> , 2013, 6, 10-16.	1.7	47
49	Immune senescence and cancer in elderly patients: Results from an exploratory study. <i>Experimental Gerontology</i> , 2013, 48, 1436-1442.	1.2	47
50	HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. <i>Human Pathology</i> , 2015, 46, 665-672.	1.1	47
51	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
52	Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 535-540.	0.9	46
53	Non-Hodgkin's lymphoma in the elderly I. Pathologic features at presentation. <i>Cancer</i> , 1990, 66, 1991-1994.	2.0	46
54	Parenteral Nutrition in Cancer Patients Receiving Chemotherapy: Effects on Toxicity and Nutritional Status. <i>Journal of Parenteral and Enteral Nutrition</i> , 1993, 17, 513-518.	1.3	44

#	ARTICLE	IF	CITATIONS
55	Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. <i>Cancer Treatment Reviews</i> , 2014, 40, 951-959.	3.4	43
56	Predictors of survival and effect of short (40ÂGy) or standard-course (60ÂGy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015, 125, 359-367.	1.4	42
57	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , 2017, 25, 3001-3004.	1.0	42
58	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
59	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e84940.	1.1	40
60	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014, 46, 182-186.	0.4	40
61	Monocytoid B-Cell Lymphoma with Bone Marrow and Peripheral Blood Involvement at Presentation. <i>American Journal of Clinical Pathology</i> , 1989, 92, 228-236.	0.4	39
62	Acute Myeloid Leukemia in the Elderly: A Critical Review of Therapeutic Approaches and Appraisal of Results of Therapy. <i>Leukemia and Lymphoma</i> , 1998, 29, 375-382.	0.6	38
63	Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches. <i>Oncologist</i> , 2011, 16, 1175-1188.	1.9	38
64	Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. <i>Supportive Care in Cancer</i> , 2019, 27, 2497-2506.	1.0	38
65	Non-Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients. <i>Cancer</i> , 1986, 57, 2185-2189.	2.0	35
66	The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2012, 19, 3737-3744.	0.7	35
67	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1523-1532.	2.0	34
68	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019, 27, 2425-2434.	1.0	34
69	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). <i>World Journal of Surgical Oncology</i> , 2014, 12, 46.	0.8	33
70	Differential expression of cell adhesion molecules in b-zone small lymphocytic lymphoma and other well-differentiated lymphocytic disorders. <i>Cancer</i> , 1993, 72, 894-904.	2.0	32
71	Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study. <i>Cancers</i> , 2021, 13, 4731.	1.7	32
72	Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs. <i>Anti-Cancer Drugs</i> , 2013, 24, 90-97.	0.7	31

#	ARTICLE	IF	CITATIONS
73	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2015, 4, 6828.	1.6	31
74	In vitro and in vivo effects of 2- β -deoxycoformycin (Pentostatin) on tumour cells from human β ² T-cell malignancies. <i>British Journal of Haematology</i> , 2000, 110, 188-196.	1.2	30
75	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 81, 38-48.	2.0	30
76	Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer. <i>Cancer Investigation</i> , 1988, 6, 1-5.	0.6	28
77	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
78	Radiomics predicts response of individual HER2 -amplified colorectal cancer liver metastases in patients treated with HER2 -targeted therapy. <i>International Journal of Cancer</i> , 2020, 147, 3215-3223.	2.3	27
79	Trastuzumab and lapatinib in HER2 -amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	0.8	27
80	Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. <i>Journal of the Turkish German Gynecology Association</i> , 2015, 16, 137-144.	0.2	27
81	B-Zone small lymphocytic lymphoma: A morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders†. <i>Human Pathology</i> , 1992, 23, 438-448.	1.1	26
82	Hepatoid Adenocarcinoma of the Colon: What Should We Target?. <i>Pathology and Oncology Research</i> , 2012, 18, 93-96.	0.9	26
83	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14.	0.6	26
84	A Phase II Study of Oral Idarubicin (4-Demethoxydaunorubicin) in Previously Untreated Elderly Patients with Non-Hodgkin's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 243-245.	0.6	25
85	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	1.3	25
86	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 336-336.	0.8	25
87	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
88	Combination Chemotherapy Specifically Devised for Elderly Patients with Unfavorable Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 1990, 8, 577-582.	0.6	24
89	Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. <i>Cancer</i> , 1999, 86, 2006-2013.	2.0	23
90	The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase II Study. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 29-36.	1.1	22

#	ARTICLE	IF	CITATIONS
91	Lesions Indefinite for Intraepithelial Neoplasia and OLGA Staging for Gastric Atrophy. American Journal of Clinical Pathology, 2012, 137, 727-732.	0.4	22
92	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	1.3	22
93	Follicular Lymphoma of Compartmentalized Small Cleaved Center Cells and Mantle Zone Lymphocytes: Evidence for a Common Derivation. American Journal of Clinical Pathology, 1992, 98, 437-448.	0.4	21
94	Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. Chemotherapy, 2014, 60, 294-299.	0.8	21
95	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial Cancer, 2015, 14, 309-316.	0.9	21
96	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	1.4	21
97	Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients. Cancers, 2019, 11, 1509.	1.7	21
98	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. Cancer, 1994, 74, 978-984.	2.0	20
99	Importance of a comprehensive geriatric assessment in older cancer patients. European Journal of Cancer, 2001, 37, 229-233.	1.3	20
100	EXPRESSION OF NATURAL KILLER ANTIGENS IN A SUBSET OF "ON-T. NON-B LYMPHOMA/LEUKAEMIA WITH HISTIOCYTIC FEATURES". British Journal of Haematology, 1990, 76, 444-448.	1.2	19
101	Hodgkin's disease: A disorder of dysregulated cellular cross-talk. Biotherapy (Dordrecht, Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.7	19
102	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. British Journal of Haematology, 1999, 105, 225-240.	1.2	19
103	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	1.9	19
104	CD13 Expression in B-Cell Chronic Lymphocytic Leukemia is Associated with the Pattern of Bone Marrow Infiltration. Leukemia and Lymphoma, 1992, 6, 209-218.	0.6	18
105	Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. Anti-Cancer Drugs, 1994, 5, 379-393.	0.7	18
106	Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2012, 69, 781-787.	1.1	18
107	Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years). Journal of Geriatric Oncology, 2013, 4, 340-345.	0.5	18
108	Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature. BioMed Research International, 2014, 2014, 1-9.	0.9	18

#	ARTICLE	IF	CITATIONS
109	HER2 amplification as a "molecular bait"™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	0.8	18
110	Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations. Cancer Medicine, 2020, 9, 9193-9204.	1.3	17
111	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
112	Intermediate lymphocytic lymphoma encompassing diffuse and mantle zone pattern variants. European Journal of Cancer & Clinical Oncology, 1989, 25, 113-121.	0.9	16
113	The Medical Oncologist's Role in Palliative Care: AIOM's Position. Tumori, 2009, 95, 652-654.	0.6	16
114	Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma. Journal of Neuro-Oncology, 2011, 104, 381-386.	1.4	16
115	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. Clinical Genitourinary Cancer, 2016, 14, e161-e169.	0.9	16
116	Changes in food habits in cancer patients in Italy: a survey. AIOM - SINPE - FAVO. Nutrition, 2018, 55-56, 140-145.	1.1	16
117	Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. Journal of Cancer, 2016, 7, 1968-1978.	1.2	15
118	Immune senescence and immune activation in elderly colorectal cancer patients. Aging, 2019, 11, 3864-3875.	1.4	15
119	Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. Anticancer Research, 2013, 33, 4061-5.	0.5	15
120	The Aged Patient with Lung Cancer. Drugs and Aging, 1994, 4, 34-46.	1.3	14
121	Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treatment Reviews, 1996, 22, 223-244.	3.4	14
122	A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute. Critical Reviews in Oncology/Hematology, 2001, 37, 153-158.	2.0	14
123	Cisplatin and Temozolomide Combination in the Treatment of Supratentorial Anaplastic Ependymoma. Chemotherapy, 2013, 59, 176-180.	0.8	14
124	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	14
125	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer, 2016, 14, 48-55.	0.9	14
126	Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas. Frontiers in Oncology, 2021, 11, 617966.	1.3	14

#	ARTICLE	IF	CITATIONS
127	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11527.	1.6	13
128	Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 289-305.	2.0	12
129	A new informed consent form model for cancer patients: Preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM). <i>Patient Education and Counseling</i> , 2012, 87, 243-249.	1.0	12
130	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	1.1	12
131	Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. <i>Journal of Neuro-Oncology</i> , 2016, 128, 481-486.	1.4	12
132	The impact of cancer on the physical function of the elderly and their utilization of health care. , 1998, 83, 589-590.		11
133	Treatment of non-Hodgkin's lymphoma in the elderly: an update. , 1998, 16, 1-13.		11
134	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11
135	Type 2 Epstein-Barr Virus Genome and Latent Membrane Protein-1 Expression in a T-Cell-Rich Lymphoma of Probable B-Cell Lineage. <i>American Journal of Clinical Pathology</i> , 1993, 100, 541-549.	0.4	10
136	Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1. <i>Clinical Cancer Research</i> , 2008, 14, 7292-7303.	3.2	10
137	PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 84-98.	2.0	10
138	An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	10
139	Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 637-642.	0.5	10
140	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A real-life study. <i>Journal of Clinical Oncology</i> , 2015, 33, 424-424.	0.8	10
141	RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). <i>Journal of Clinical Oncology</i> , 2015, 33, 512-512.	0.8	10
142	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017, 8, 55575-55581.	0.8	10
143	EXPRESSION OF MYELOID ASSOCIATED ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKAEMIA. <i>British Journal of Haematology</i> , 1992, 82, 173-175.	1.2	9
144	Consensus document of the Italian Association of Medical Oncology and the Italian Society of Palliative Care on early palliative care. <i>Tumori</i> , 2019, 105, 103-112.	0.6	9

#	ARTICLE	IF	CITATIONS
145	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). <i>Frontiers in Oncology</i> , 2021, 11, 787835.	1.3	9
146	Phase II study of teniposide (VM-26) in multiple myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1985, 8, 329-331.	0.6	8
147	Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous t-cell lymphomas. <i>Hematological Oncology</i> , 1986, 4, 83-90.	0.8	8
148	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	1.1	8
149	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	1.1	8
150	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	1.3	8
151	Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. <i>Human Pathology</i> , 2012, 43, 1839-1844.	1.1	7
152	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 679-685.	1.2	7
153	Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2019, 30, 533-536.	0.7	7
154	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3648-TPS3648.	0.8	7
155	Age as a Risk Factor for Inadequate Treatment. <i>JAMA - Journal of the American Medical Association</i> , 1988, 259, 41.	3.8	6
156	Common errors in conducting and reporting clinical trials in non-Hodgkin lymphomas and patients' age. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 811.	0.9	6
157	An update on the diagnostic relevance of CD26 antigen expression in CD30 positive anaplastic large cell lymphomas. <i>Human Pathology</i> , 1995, 26, 1169-1170.	1.1	6
158	Rarity of microsatellite genomic instability in B-cell non-Hodgkin's lymphomas in hepatitis C virus-infected patients. <i>British Journal of Haematology</i> , 1997, 97, 463-465.	1.2	6
159	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3524-3524.	0.8	6
160	Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. <i>Anticancer Research</i> , 2010, 30, 5213-6.	0.5	6
161	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. <i>Cancers</i> , 2022, 14, 2568.	1.7	6
162	Is burnout affecting life satisfaction in oncologists? The moderating role of family concerns in an Italian sample. <i>Psycho-Oncology</i> , 2021, 30, 385-391.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Practical Importance of Routine Paraffin-Embedded Bone Marrow Biopsy in Multiple Myeloma. Tumori, 1987, 73, 315-319.	0.6	4
164	Phase II study of esorubicin (4?-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. Investigational New Drugs, 1987, 5, 307-9.	1.2	4
165	Serum levels of adhesion molecules in haematopoietic tumours. Trends in Immunology, 1994, 15, 339.	7.5	4
166	Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access Journal of Urology, 2011, 3, 69.	0.3	4
167	Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural economic status, awareness of disease and the relation with the oncologist. European Journal of Internal Medicine, 2016, 33, e18-e19.	1.0	4
168	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. Future Oncology, 2016, 12, 909-919.	1.1	4
169	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. Journal of Clinical Oncology, 2015, 33, 412-412.	0.8	4
170	Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments. Tumori, 1988, 74, 433-438.	0.6	3
171	Phase II Study of Teniposide (VM26) in Cutaneous T-Cell Lymphomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1990, 13, 14-16.	0.6	3
172	Gliomas. BioMed Research International, 2014, 2014, 1-2.	0.9	3
173	Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement. Tumori, 2016, 102, e25-e27.	0.6	3
174	Urine 2-Hydroxyglutarate in Glioma. Oncologist, 2016, 21, 1026-1026.	1.9	3
175	Second medical opinion in oncological setting. Critical Reviews in Oncology/Hematology, 2021, 160, 103282.	2.0	3
176	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial. , 2016, , .		3
177	Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. Targeted Oncology, 2022, 17, 467-474.	1.7	3
178	Bone Marrow Involvement in Cutaneous T-Cell Lymphoma. American Journal of Clinical Pathology, 1990, 94, 119-120.	0.4	2
179	Re: Chronically Depressed Mood and Cancer Risk in Older Persons. Journal of the National Cancer Institute, 1999, 91, 1080-1080.	3.0	2
180	âœœCare and Self-CareâœœGod as a Mirror of the Selfâœœ. Journal of Cancer Education, 2009, 24, 80-82.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Cilengitide in bevacizumab-refractory high-grade glioma. <i>Anti-Cancer Drugs</i> , 2012, 23, 749-753.	0.7	2
182	The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience. <i>BioMed Research International</i> , 2014, 2014, 1-4.	0.9	2
183	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2018, 57, 412-419.	0.8	2
184	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. <i>Anti-Cancer Drugs</i> , 2018, 29, 924-928.	0.7	2
185	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3664-TPS3664.	0.8	2
186	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 565-565.	0.8	2
187	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338.	1.7	2
188	An Overview of Intracranial Ependymomas in Adults. <i>Cancers</i> , 2021, 13, 6128.	1.7	2
189	Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera Statement.. <i>ESMO Open</i> , 2022, , 100538.	2.0	2
190	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	1
191	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2047-2047.	0.8	1
192	A phase III multicenter trial comparing two different sequences of second/third line therapy		

#	ARTICLE	IF	CITATIONS
199	Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma.. Journal of Clinical Oncology, 2014, 32, 2037-2037.	0.8	0
200	Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heavily pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2014, 32, e15255-e15255.	0.8	0
201	Aromatase inhibitors in elderly patients with advanced breast cancer: An exploratory pharmacogenetic study.. Journal of Clinical Oncology, 2014, 32, 11058-11058.	0.8	0
202	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (MO) colorectal cancer (CRC)?. Journal of Clinical Oncology, 2015, 33, 650-650.	0.8	0
203	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2015, 33, 206-206.	0.8	0
204	Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. Journal of Clinical Oncology, 2015, 33, 225-225.	0.8	0
205	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. Journal of Clinical Oncology, 2015, 33, e13003-e13003.	0.8	0
206	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. Journal of Clinical Oncology, 2016, 34, 549-549.	0.8	0
207	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2016, 34, 211-211.	0.8	0
208	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience.. Journal of Clinical Oncology, 2016, 34, 733-733.	0.8	0
209	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. Tumori, 2013, 99, 122-4.	0.6	0